Antithrombin III for critically ill patients

Antithrombin III (AT III) cannot be recommended for critically ill patients based on the available evidence.

Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. AT III is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown. This review assesses the benefits and harms of AT III in critically ill patients.

The Evidence Aid website is currently undergoing development for an optimized user experience. Normal website use should be unaffected but please allow for any unexpected disruption during this period and apologies for any inconvenience. Ok